Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abatacept - Bristol-Myers Squibb

Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cambridge University Hospitals; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Medical Center Freiburg; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins; Skin disorder therapies
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Lupus nephritis; Myositis; Sjogren's syndrome
  • Phase II Common variable immunodeficiency; Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome; Pulmonary sarcoidosis
  • Preclinical Inflammation
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 11 Dec 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis in United Kingdom and Netherlands (ISRCTN46017566)
  • 13 Nov 2018 Bristol-Myers Squibb initiates enrolment in a phase II trial for Immunological disorders (IgG4-related disease) in the US (SC) (NCT03669861)
  • 22 Oct 2018 Bristol-Myers Squibb plans a phase I trial for healthy volunteers in November 2018 (NCT03714022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top